Promising breast cancer drug trial pulled before starting
Disease control
Terminated
This study aimed to see if the drug trastuzumab deruxtecan worked better than standard CDK4/6 inhibitors for people with a specific advanced breast cancer (ER-positive, HER2-low, non-luminal A). It was designed for adults with metastatic disease. However, the trial was withdrawn …
Phase: PHASE3 • Sponsor: Danish Breast Cancer Cooperative Group • Aim: Disease control
Last updated Jun 17, 2026 12:07 UTC